Farzadegan H, Shamszad M, Noori-Arya K
Ann Acad Med Singap. 1980 Apr;9(2):144-8.
Our studies revealed that the incidence of viral hepatitis in Iran is more common than in the western countries. Although the incidence of hepatitis type A in the region is not thoroughly investigated, our first report on this disease in our region reveals an almost complete immunity among adults after 30 years of age. The incidence of HBsAg among our voluntary blood donors is 3.5%. If it is assumed that the incidence rate in the whole country is also 3.5%, then it is possible that there are one million HBsAg carriers among 35 million Iranians. These carriers constitute a major health problem in Iran. There is a good possibility that the HBsAg incidence rate in the other countries of the region is similarly high. Therefore it is highly recommended that control and preventive measures such as third generation HB teting of donated blood and blood products become mandatory. All HBsAg positive donors should be interviewed and informed that their blood contains an infectious agent and this must be carefully considered at the times of bleeding. Other high risk groups such as haemodialysis patients and staff and haemophiliacs also should be investigated as possible candidates for HB vaccination.
我们的研究表明,伊朗病毒性肝炎的发病率比西方国家更为常见。尽管该地区甲型肝炎的发病率尚未得到全面调查,但我们在本地区关于这种疾病的首份报告显示,30岁以上的成年人几乎具有完全免疫力。我们的无偿献血者中乙肝表面抗原(HBsAg)的发病率为3.5%。如果假设全国的发病率也是3.5%,那么在3500万伊朗人中可能有100万HBsAg携带者。这些携带者构成了伊朗的一个主要健康问题。该地区其他国家的HBsAg发病率很可能同样很高。因此,强烈建议将诸如对献血和血液制品进行第三代乙肝检测等控制和预防措施强制实施。所有HBsAg阳性献血者都应接受询问,并告知他们的血液含有感染源,在出血时必须对此予以谨慎考虑。其他高危人群,如血液透析患者及其工作人员和血友病患者,也应作为乙肝疫苗接种的可能对象进行调查。